Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC). The company's primary purpose is to identify and merge with a private company. Now — the numbers.
There is not enough trading history here to call this an established business.
If every debt were paid off today, $6K would still be left — though next to the size of the company that is a thin cushion.
The market pays 60.2× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 24% of them.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 12 months, company executives reported 12 buys and 4 sells. Management buying with its own money is usually read as a good sign.
The growth engine is running at low revs right now. Report-card grade: 11/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 14/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 24/100.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.